The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Centessa Pharmaceuticals plc (NASDAQ: CNTA) who purchased : (a) American Depositary Shares pursuant and/or traceable to documents issued in connection with the Company’s initial public offering conducted on or about May 28, 2021; and/or (b) Centessa securities between May 28, 2021 and June 1, 2022. The action, which was filed in the United States District Court for the Central District of California, alleges that the Company violated federal securities laws.
In particular, the Centessa lawsuit alleges that (i) the Company’s product, lixivaptan, was less safe than defendants had represented; (ii) defendants overstated lixivaptan’s clinical and commercial prospects; (iii) another Centessa product, ZF874, was less safe than defendants had represented; (iv) defendants overstated ZF874’s clinical and commercial prospects while downplaying the drug’s safety issues; and (v) as a result, documents issued in connection with Centessa’s initial public offering and the Company’s public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
Shareholders have until November 28, 2022 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
To learn more and keep informed, complete this form >